FDA asks social media "how'm I doin?"

Share this article:

The FDA's Center for Drug Evaluation and Research's Office of Communications wants to get a sense of how well it's doing in terms of social media, and has outlined a project which it hopes will provide just this type of feedback.

The Statement of Work says the division wants a subscription service which will “manage and monitor traditional and social media service” so the FDA group can “monitor and measure the message reach and sentiment in real time” and “gain access to the message impact to the geographic area.” CDER's communication folks also want to be able to identify influencers and have the opportunity to “target communication and address information gaps.”

The statement of work shows that FDA is not just talking text—it wants to be able to assess photos, audio and video posts. The FDA also wants to capture as much chatter as possible, which means tracking channels as varied as blogs, forums and e-commerce sites, as opposed to relying on only traditional media outlets.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.